Tofacitinib Results in Rapid Resolution of Treatment-Refractory Anti–PD-1–Associated Colitis and Reversal of CD8+ Tissue Resident Memory T Cell Activation and Interferon-Gamma Signaling. This evidence concerns the gene CD8A and colitis.